These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38890776)

  • 1. The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile.
    Alafraidi M; Hoang L; Howitt BE; Longacre TA; McAlpine JN; Jamieson A; Singh N; Gilks CB; Pors J
    Histopathology; 2024 Oct; 85(4):660-670. PubMed ID: 38890776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
    Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
    Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
    Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
    Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
    Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
    Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
    Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesonephric-like Endometrial Carcinoma: Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity.
    Mills AM; Jenkins TM; Howitt BE; Fan J; Ring KL; Cook I
    Am J Surg Pathol; 2022 Jul; 46(7):921-932. PubMed ID: 35195579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
    Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
    Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
    Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
    Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
    McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
    Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor Immunohistochemical Expression in Undifferentiated/Dedifferentiated Endometrial Carcinoma.
    Cao J; Hacking S; Chavarria-Bernal HD; Bhuiya TA; Khutti S
    Int J Gynecol Pathol; 2022 Jan; 41(1):28-34. PubMed ID: 33399351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
    Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
    Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report.
    Yano M; Shintani D; Katoh T; Hamada M; Ito K; Kozawa E; Hasegawa K; Yasuda M
    Diagn Pathol; 2019 Jun; 14(1):54. PubMed ID: 31174566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases.
    Mhawech-Fauceglia P; Yan L; Liu S; Pejovic T
    Histopathology; 2013 Jun; 62(7):976-85. PubMed ID: 23570281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.